Home › Products › Oncology › Lenvanamo 10mg Capsule
Lenvanamo 10mg Capsule
Salt Composition: LENVATINIB
- Manufacturer: SHIVNAAM TRADELINK LLP
- Pack Size: 30 CAPSULE(s) IN A BOTTLE
- Dosage Form: CAPSULE
- Strength: 10MG
- Prescription Required
- Storage: Lenvanamo 10mg Tablet should be stored at room temperature, between 20°C to 25°C (68°F to 77°F). Protected from light. Keep it in its original packaging until it is ready to be used. Keep out of the reach of children and pets. It should be disposed of properly.
₹4608.00₹11521.00
Inclusive of all taxes
Product Introduction
Lenvanamo 10mg Capsule contains the active ingredient Lenvatinib, a tyrosine kinase inhibitor. It is indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment. Anaplastic thyroid carcinoma (advanced thyroid cancer) typically occurs in patients above 60 years of age. It is characterised by an enlarged and hard thyroid gland and hoarseness in the voice due to paralysis of the nerve in the voice box. Hepatocellular carcinoma (liver cancer) develops due to preexisting liver conditions such as cirrhosis or chronic hepatitis B infection. Patients who have had an allergic reaction to Lenvanamo 10mg Capsule or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking Lenvanamo 10mg Capsule, as it can impair wound healing and increase the risk of bleeding.
Uses
Lenvanamo 10mg Tablet is indicated to treat the following conditions: Certain types of advanced thyroid cancer Advanced Liver cancer Certain types of kidney cancer Endometrial cancer
How it works
Lenvanamo 10mg Tablet blocks the enzyme receptor tyrosine kinases (RTKs). RTKs develop new blood vessels that supply oxygen and nutrients to the cells and help them grow. This medicine inhibits the receptors that facilitate the growth of blood vessels in tumour cells. RTKs are present in high concentrations in cancer cells, and administration of this medicine slows down the rate of cancer cellsâ growth and multiplication.
How to Use
Lenvanamo 10mg Tablet is an oral medication that is usually taken once a day, at approximately the same time each day, with or without food. It should be taken as prescribed by a doctor or other healthcare provider. These capsules should be swallowed whole with a glass of water. They should not be crushed, chewed, or opened, as this can affect the way the medication is absorbed and decrease its effectiveness. You should not take a double dose to make up the second dose.
Side Effects
Like all medications, Lenvanamo 10mg Tablet can cause side effects, although not everyone who takes it will experience them. Serious: Liver toxicity or liver failure Heart problems, such as heart attack Hemorrhage (bleeding) Blood clots Poor wound healing Kidney failure Hypothyroidism Skin reactions (rash or blisters) Common: Fatigue Loss of appetite Weight loss Nausea and vomiting Diarrhea Stomach pain or discomfort Hypertension (high blood pressure) Headache Joint pain or muscle pain Changes in taste
Expert Tips
If you are receiving close communication with your healthcare provider and report any concerns or side effects as soon as possible. Avoid getting pregnant and breastfeeding during treatment. Patients should use effective contraception while taking Lenvanamo 10mg Tablet and for at least two weeks after stopping treatment. Patients should avoid eating grapefruits as they affect the absorption of this drug. Patients should use sunscreen and wear protective clothing while outdoors to reduce the risk of sunburn or skin damage. You should avoid strenuous activities or exercise until you know how this medication is affecting you. Maintain a healthy and balanced diet during treatment to support your overall health and well-being. By being informed and engaged in your treatment, you can help ensure the best possible outcomes and manage any potential risks or complications associated.
References
- Eisai Europe Limited, Electronic Medicines Compendium (EMC), [Revised on Mar 2021] [Accessed on 20th April 2023], https://www.medicines.org.uk/emc/files/pil.6840.pdf
- Suyama and Iwase, Lenvatinib: A promising molecular targeted agent for multiple cancers, Cancer Control, 2018, 25, 1-5, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056795/pdf/10/1177 1073274818789361.pdf
- Q.M. Anstee, D.E.J. Jones, Liver and Biliary Tract Disease, Davidsonâs Principles and Practice of Medicine, 22nd Edition, 2014, 921-988.
- M.W.J. Strachan, J. Newell-Price, Endocrine disease, Davidsonâs Principles & Practice of Medicine, 22nd Edition, 2014, 733-796.
- Eisai Inc U.S Food and Safety Drug Administration (FDA) [Last revised Aug 2018], [Accessed on 20th April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206947s007lbl.pdf
Safety Advice
Pregnancy: unsafe Lenvanamo 10mg Tablet is unsafe during pregnancy as it can cause fetal harm. It is s recommended to avoid this medication during pregnancy.
Lungs: unsafe Lenvanamo 10mg Tablet can cause side effects that affect the lungs, such as cough, shortness of breath, and difficulty breathing. If a person experiences any of these symptoms while taking it, they should notify their healthcare provider right away.
Breastfeeding: unsafe Breastfeeding is not recommended while taking Lenvanamo 10mg Tablet, as it can potentially harm the nursing infant.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.